antiviral and associated therapy - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
ivermectin	11 studies[1]	0.94 [0.77 ; 1.15], 3 RCTs, I2=0% inconclusive result	1.07 [0.98 ; 1.17], 2 RCTs, I2=0% inconclusive result	0.93 [0.54 ; 1.59], 4 RCTs, I2=0% inconclusive result	0.92 [0.77 ; 1.09], 2 RCTs, I2=0% inconclusive result
chloroquine and derivatives	8 studies[2]	0.51 [0.07 ; 3.68], 1 RCT, I2=0% inconclusive result	1.36 [0.87 ; 2.11], 1 RCT, I2=0% inconclusive result	1.32 [0.44 ; 3.93], 5 RCTs, I2=0% inconclusive result	0.93 [0.62 ; 1.40], 2 RCTs, I2=0% inconclusive result
azithromycin	4 studies[3]	-	1.08 [0.95 ; 1.23], 1 RCT, I2=0% inconclusive result	1.65 [0.03 ; 83.12], 1 RCT, I2=0% inconclusive result	715.00 [12.94 ; 39513.71], 1 study, I2=0% certainty unassessable
fluvoxamine	4 studies[4]	0.72 [0.45 ; 1.16], 3 RCTs, I2=61% demonstrated inconclusive result	-	0.80 [0.43 ; 1.50], 1 RCT, I2=0% inconclusive result	0.67 [0.42 ; 1.06], 1 RCT, I2=0% inconclusive result
hydroxychloroquine plus macrolides	2 studies[5]	-	-	-	0.91 [0.54 ; 1.51], 2 RCTs, I2=0% inconclusive result
molnupiravir	2 studies[6]	-	-	0.10 [0.01 ; 0.92], 2 RCTs, I2=0% high degree of certainty	14.50 [1.70 ; 123.69], 1 RCT, I2=0% certainty unassessable
lopinavir/ritonavir	1 study[7]	-	-	0.26 [0.01 ; 5.88], 1 RCT, I2=0% inconclusive result	0.92 [0.82 ; 1.03], 1 RCT, I2=0% inconclusive result
nirmatrelvir / ritonavir (Paxlovid)	1 study[8]	-	-	0.04 [0.00 ; 0.70], 1 RCT, I2=0% certainty unassessable	-
nitazoxanide	1 study[9]	-	-	-	-
remdesivir	1 study[10]	-	-	1.01 [0.02 ; 51.30], 1 RCT, I2=0% inconclusive result	-

Continued on next page

Downloaded from www.metaEvidence.org

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
sofosbuvir and daclatasvir	1 study[11]	-	-	-	-
zinc	1 study[12]	-	-	-	-

Notes

[1]ACTIV-6 (ivermectine), 2023 (NCT04885530) ; ACTIV 6 ivermectin, 2022 (NCT04885530) ; COVID-OUT (ivermectin), 2022 (NCT04510194) ; TOGETHER (ivermectine), 2022 (NCT04727424) ; Lopez-Medina, 2021 (NCT04405843) ; Chaccour, 2020 (NCT04390022) ; Chowdhury A, 2020 (NCT04434144) ; IVERCORCOVID19 (Vallejos), 2020 (NCT04529525) ; Podder, 2020 () ; Chahla, 2021 (NCT04784481) ; Espitia-Hernandez, 2020 ()

[2]COPE – Coalition V, 2022 (NCT04466540) ; PATCH Cohort 1 (Amaravadi), 2021 (NCT04329923) ; Reis (Hydroxychloroquine) (TOGETHER), 2021 (NCT04403100) ; BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 (NCT04304053) ; COMIHY, 2020 (NCT04340544) ; COVID-PEP Severity (Skipper), 2020 (NCT04308668) ; Q-PROTECT -HCQ alone, 2020 (NCT04349592) ; Agusti, 2020 ()

[3]ACTION, 2021 (NCT04332107) ; Hinks (ATOMIC2), 2021 (NCT04381962) ; PRINCIPLE, 2021 (ISRCTN86534580) ; Espitia-Hernandez, 2020 ()

[4]ACTIV-6, 2022 (NCT04885530) ; COVID-OUT (fluvoxamine), 2022 (NCT04510194) ; TOGETHER, 2021 (NCT04727424) ; Lenze (STOP COVID 1), 2020 (NCT04342663)

[5]Rodrigues, 2021 () ; Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 (NCT04349592)

[6]Fischer (all doses), 2021 (NCT04405570) ; MOVe-OUT, 2021 (NCT04575597)

[7]Reis (Lopinavir-ritonavir) (TOGETHER), 2021 (NCT04403100)

[8]EPIC-HR, 2021 (NCT04960202)

[9]RM08-3008 (Rossignol), 2021 (NCT04486313)

[10]PINETREE (GS-US-540-9012), 2021 (NCT04501952)

[11]Roozbeh, 2020 (IRCT20200403046926N1)

[12]Thomas (zinc only), 2021 (NCT04342728)

Downloaded from www.metaEvidence.org